Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Tagrisso (osimertinib) is recommended as an adjuvant treatment after complete tumour resection in adults with stage IB-IIIA non-small cell lung cancer (NSCLC) with specific genetic mutations. This ...

1,3 Tagrisso (osimertinib) received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumour resection in adult patients with stage IB-IIIA non-small cell ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC ...

It's never too late to stop smoking. About 90% of lung cancers are attributable to smoking, and smokers have a 20-fold higher lifetime risk for developing lung cancer than do nonsmokers.